Therapeutic Asset Ratings
8,400 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Entacapone
Autonomic Nervous System Disorder
Daniel Claassen
P1/2
CCC
(54)
Entinostat
Central Nervous System Neoplasm
University Hospital Heidelberg
P1/2
CCC
(54)
Epirubicin
Gliomas, Malignant
Essen Biotech
P1/2
CCC
(54)
Epirubicin
Ureteral Neoplasms
Eli Lilly and Company
P1/2
CCC
(54)
Eribulin
Soft Tissue Sarcoma
GI Innovation, Inc.
P1/2
CCC
(54)
Everolimus
Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
P1/2
CCC
(54)
Evofosfamide
Head And Neck Squamous Cell Carcinoma
ImmunoGenesis
P1/2
CCC
(54)
exg001-307
Spinal Muscular Atrophy, Type 1
Guangzhou Jiayin Biotech Ltd
P1/2
CCC
(54)
FALLYPRIDE
NHL
National Cancer Institute (NCI)
P1/2
CCC
(54)
Fludarabine
Prostate Adenocarcinoma
Beijing Biotech
P1/2
CCC
(54)
Fludarabine
HER2-positive Breast Cancer
National University Hospital, Singapore
P1/2
CCC
(54)
Fludarabine
Myxoid/Round Cell Liposarcoma
Sotio Biotech Inc.
P1/2
CCC
(54)
FULVESTRANT
Esophageal SCC
Terremoto Biosciences Inc.
P1/2
CCC
(54)
FULVESTRANT
Fallopian Tube Cancer
Atavistik Bio, Inc
P1/2
CCC
(54)
gt719
Hematopoietic And Lymphoid System Neoplasm
Grit Biotechnology
P1/2
CCC
(54)
HAFNIUM OXIDE
Non-Small Cell Lung Carcinoma
M.D. Anderson Cancer Center
P1/2
CCC
(54)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Beta-Thalassemia Major
M.D. Anderson Cancer Center
P1/2
CCC
(54)
Ipilimumab
Cutaneous Neuroendocrine Carcinoma
National Cancer Institute (NCI)
P1/2
CCC
(54)
Ipilimumab
Skin Squamous Cell Carcinoma
National Cancer Institute (NCI)
P1/2
CCC
(54)
Ipilimumab
Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
P1/2
CCC
(54)
Irinotecan
Anaplastic Glioma
City of Hope Medical Center
P1/2
CCC
(54)
Irinotecan
Digestive System Carcinoma
National Cancer Institute (NCI)
P1/2
CCC
(54)
Irinotecan
Malignant Thoracic Neoplasm
Tango Therapeutics, Inc.
P1/2
CCC
(54)
Irinotecan
Uterine Cancer
City of Hope Medical Center
P1/2
CCC
(54)
Irinotecan
Recurrent Thyroid Gland Carcinoma
Institut de Recherches Internationales Servier
P1/2
CCC
(54)
Showing 326 to 350 of 8,400 assets
Previous
Page 14 of 336
Next